Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7572920 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL897301 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL9831661 | 0.95 | CYP1A2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12243010 | 0.95 | CHRNB2 (0.34) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL10519781 | 0.95 | CYP1A2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL21129873 | 0.92 | CYP1A2 (0.42) | CHRNB2CHRNA7CHRNA4CYP1A2 | |
| SCHEMBL21120996 | 0.92 | CYP1A2 (0.42) | CHRNB2CHRNA7CHRNA4CYP1A2 | |
| SCHEMBL6111083 | 0.92 | CYP1A2 (0.42) | CHRNB2CHRNA7CHRNA4CYP1A2 | |
| SCHEMBL12388313 | 0.92 | CYP1A2 (0.38) | CHRNB2CHRNA7CHRNA4CYP1A2TDP1 | |
| SCHEMBL12243011 | 0.90 | CYP1A2 (0.41) | CHRNB2CHRNA7CHRNA4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| CN-103265477-B | Aminoheteroaryl compounds as protein kinase inhibitors | 苏根公司 | 2017-01-11 | — | — | CN | disclosed |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| EP-1446117-A4 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN INC (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1599207-A2 | TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS | Sugen, Inc. (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1562600-A2 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | Sugen, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004075775-A2 | TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-1446117-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | Sugen, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1434774-A1 | 3-(4-SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004045523-A2 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003035009-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003031438-A1 | 3-[4-(SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE]-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-4874488-A | USING MERCURY CATALYST AND ULTRAVIOLET RADIATION | YALE UNIVERSITY (US) | 1989-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CHRNB2 1541/4885CHRNB4 1433/4885CHRNA3 972/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CHRNB2 1541/4885CHRNB4 1433/4885CHRNA3 972/4885 |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | CHRNB2 1541/4885CHRNB4 1433/4885CHRNA3 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.